MDR- and CYP3A4-mediated drug-drug interactions

Journal of Neuroimmune Pharmacology

Volumn 1, Issue 3, 2006, Pages 323-339

  Pal, Dhananjay ^a   Mitra, Ashim K ^a  

^a UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

Author keywords

CYP3A4; Drug drug interactions; MDR; Protease inhibitors

Indexed keywords

CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450; DRUG; MULTIDRUG RESISTANCE PROTEIN; PROTEINASE INHIBITOR;

ANIMAL; CONFERENCE PAPER; DRUG EFFECT; DRUG INTERACTION; HUMAN; METABOLISM; PHYSIOLOGY;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; PHARMACEUTICAL PREPARATIONS; PROTEASE INHIBITORS;

EID: 33747352798     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-006-9034-2     Document Type: Conference Paper

References (114)

1. Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA et al (2003) Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med 139:258-266
2. Agarwala S, Mummaneni V, Randall D et al (2002) Pharmacokinetic effect of rifabutin on atazanavir with and without ritonavir in healthy subjects [abst #445]. 9th Conference on Retroviruses and Opportunistic Infections; Feb 24-28; Seattle, Washington
3. Agenerase [package insert]. Research Triangle Park, NC: Glaxo Wellcome Inc; 2004
4. Albengres E, Le Louet H, Tillement JP (1998) Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 18:83-97
5. Altice F, Friedland G, Cooney E (1999) Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone. AIDS 13:957-962
6. Ambudkar SV, Dey S, Hrycyna CA, Ramachandra M, Pastan I, Gottesman MM (1999) Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 39:361-398
7. Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM (2003) P-glycoprotein: from genomics to mechanism. Oncogene 22:7468-7485
8. Aptivus [package insert] (2005) Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, Inc.; Nov
9. Armstrong SC, Cozza KL (2003a) Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I. Psychosomatics 44:167-171
10. Armstrong SC, Cozza KL (2003b) Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part II. Psychosomatics 44:515-520
11. Bakos E, Evers R, Sinko E et al (2000) interactions of the human multidrug resistance proteins MRP1 and MRP2 with organic anions. Mol Pharmacol 57:760-768
12. Bart PA, Rizzardi PG, Gallant S, Golay KP, Baumann P, Pantaleo G, Eap CB (2001) Methadone blood concentrations are decreased by the administration of abacavir plus amprenavir. Ther Drug Monit 2001:23:553-555
13. Beauverie P, Taburet AM, Dessalles MC, Furlan V, Touzeau D (1998) Therapeutic drug monitoring of methadone in HIV-infected patients receiving protease inhibitors (letter). AIDS 12:2510-2511
14. Bellibas SE (1999) Indinavir-fluconazole interaction. [letter] Antimicrob Agents Chemother 43:432-433
15. Bornheim L (1998) Effect of cytochrome P450 inducers on cocaine-mediated hepatotoxicity. Toxicol Appl Pharmacol 150:158-165
16. Borst P, Schinkel AH, Smit JJ, Wagenaar E et al (1993) Classical and novel forms of multidrug resistance and the physiological functions of P-glycoproteins in mammals. Pharmacol Ther 60:289-299
17. Borst P, Evers R, Kool M, Wijnholds J (2000) A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 92:1295-1302
18. Boruchoff SE, Sturgill MG, Grasing KW et al (2000) The steady-state disposition of indinavir is not altered by the concomitant administration of clarithromycin. Clin Pharmacol Ther 67:351-359
19. Brinkman K et al (1998) Pharmacokinetic interaction between saquinavir and cyclosporine. Ann Intern Med 129:914-915
20. Brophy DF, Israel DS, Pastor A et al (2000) Pharmacokinetic interaction between amprenavir and clarithromycin in healthy male volunteers. Antimicrob Agents Chemother 44:978-984
21. Burger D, Agarwala S, Child M et al (2005) Effect of rifampin on steady-state pharmacokinetics of atazanavir and ritonavir in healthy subjects [abst #657]. 12th Conference on Retroviruses and Opportunistic Infections; February 22-25; Boston, Massachusetts
22. Cardiello PG, Samor T, Burger D et al (2003) Pharmacokinetics of lower doses of saquinavir soft-gel caps boosted with itraconazole in HIV-1 positive patients. Antivir Ther 8:245-249
23. Carr RA, Andre AK, Bertz RJ et al (2000) Concomitant administration of ABT-378/ritonavir. Results in a clinically important pharmacokinetic interaction with atorvastatin but not pravastatin [abst #1644]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20; Toronto, Canada
24. Cato A, Cao G, Hsu A et al (1997) Evaluation of the effect of fluconazole on the pharmacokinetics of ritonavir. Drug Metab Dispos 25:1104-1106
25. Cato A, Cavanaugh J, Shi H et al (1998) The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther 63:414-421
26. CDC (2000a) Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Jan 28, [AIDS Treatment Information Service: Current Treatment], Available at: http://www.hivatis.org/trtgdlns.html
27. CDC (2000b) Notice to readers: updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected individuals taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR 49:185-189
28. Chiou WL, Chung SM, Wu TC (2000) Potential role of P-glycoprotein in affecting hepatic metabolism of drugs. Pharm Res 17:903-905
29. Cole SP, Bhardwaj G, Gerlach JH et al (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258:1650-1654
30. Crixivan [package insert]( 2005) Whitehouse Station, NJ: Merck & Co., Inc.; Oct
31. Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB (1999) OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 27:866-871
32. Decker CJ, Laitinen LM, Bridson GW et al (1998) Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci 87:803-807
33. Deeley RG, Cole SP (1997) Function, evolution and structure of multidrug resistance protein (MRP). Semin Cancer Biol 8:193-204
34. de la Torre R, Farre M, Ortuno J, Mas M, Brenneisen R et al (2000) Non-linear pharmacokinetics of MDMA ("Ecstasy") in humans. Br J Clin Pharmacol 49:104-109
35. Department of Health and Human Services (2001) Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. August 13
36. DeWit S, Debier M, DeSmet M et al (1998) Effect of fluconazole on indinavir pharmacokinetics in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother 42:223-227
37. Endicottaland JA, Ling V (1989) The biochemistry of P-glycoprotein- mediated multidrug resistance. Annu Rev Biochem 58:137-171
38. Fiske W, Benedek IH et al (1998) Pharmacokinetics of efavirenz (EFV) and ritonavir (RIT) after multiple oral doses in healthy volunteers [abst. #42269]. 12th International Conference on AIDS; June 28-July 3; Geneva, Switzerland
39. Foulds G, LaBoy-Goral L, Wei GCG et al (1999) The effect of azithromycin on the pharmacokinetics of indinavir. J Clin Pharmacol 39:842-846
40. Fortovase [package insert] (2003) Basel, Switzerland: F. Hoffman-La Roche Ltd
41. Gottesman MM, Pastan I (1993) Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62:385-427
42. Gottesman MM, Pastan I' Ambudkar SV (1996) P-glycoprotein and multidrug resistance. Curr Opin Genet Dev 6:610-617
43. Greenblatt DJ, von Moltke LL, Harmatz JS, Durol AL, Daily JP, Graf J, Mertzanis P, Hoffman JL, Shader RI (2000) Alprazolam-ritonavir interaction: implications for product labeling. Clin Pharmacol Ther 67:335-341
44. Greiner B, Eichelbaum M, Fritz P (1999) The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 104:147-153
45. Grub S, Bryson H, Goggin T et al (2001) The interaction of saquinavir with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients. Eur J Clin Pharmacol 57:115-121
46. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DJ (1986) Characterization of rat and human liver microsomal cytochrome P-450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051-5060
47. Hamzeh F, Benson C, Gerber J et al (2000) Steady-state pharmacokinetic interaction of modified-dose indinavir and rifabutin [abst #90]. 7th Conference on Retroviruses and Opportunistic Infections; Jan 30-Feb 2; San Francisco, California
48. Handschin C, Meyer UA (2003) Induction of drug metabolism: the role of nuclear receptors. Pharmacol Rev 55:649-673
49. Harrington RD, Woodward JA, Hooton TM, Horn JR (1999) Life-threatening interactions between HIV-1 protease inhibitors and the illicit drugs MDMA and gamma-hydroxybutyrate. Arch Intern Med 159:2221-2224
50. Henry J, Hill I (1998) Fatal interaction between ritonavir and MDMA. Lancet 352:1751-1752
51. Hofsliand E, Nissen-Meyer J (1989) Reversal of drug resistance by erythromycin: erythromycin increases the accumulation of actinomycin D and doxorubicin in multidrug-resistance cells. Int J Cancer 44:149-154
52. Hsu A, Granneman GR, Bertz RJ, Ritonavir (1998) Clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 35:275-291
53. Hsyu PH, Schultz-Smith MD, Lillibridge JH et al (2001) Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 45:3445-3450
54. Huisman MT, Smit JW, Crommentuyn KM et al (2002) Multidrug resistance protein 2 (MRP2) transport HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS 16:2295-2301
55. Hulot JS, Villard E, Maguy A et al (2005) A mutation in the drug transporter gene ABCC2 associated with impaired methotrexate elimination. Pharmacogenet Genomics 15:277-285
56. Kaletra [package insert] (2005) North Chicago, IL: Abbott Laboratories; Oct
57. Katoh M, Nakajima M, Yamazaki H, Yokoi T (2001) Inhibitory effects of CYP3A4 substrates and their metabolites on P-glycoprotein-mediated transport. Eur J Pharm Sci 12:505-513
58. Katragadda S, Budda B, Anand BS, Mitra AK (2005) Role of efflux pumps and metabolizing enzymes in drug delivery. Expert Opin Drug Deliv 2:683-705
59. Ketabi-Kiyanvash N, Weiss J, Haefeli WE, Mikus G (2003) P-glycoprotein modulation by the designer drugs methylenedioxymethamphetamine, methylenedioxyethylamphetamine, and paramethoxyamphetamine. Addict Biol 8:413-418
60. Koks CH, Crommentuyn KM, Hoetelmans RM et al (2001) The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1 infected individuals. Br J Clin Pharmacol 51:631-635
61. Kolars JC, Schmiedlin-Ren P, Schuetz JD, Fang C, Watkins PB (1992) Identification of rifampin-inducible P540IIIA4 (CYP3A4) in human small bowel enterocytes. J Clin Invest 90:1871-1878
62. Kosel BW, Aweeka FT, Benowitz NL, Shade SB et al (2002) The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 16:534-550
63. Krishnamachary N, Center MS (1993) MRP gene associated with a non-P-glycoprotein multidrug resistance encode a 190-kDa membrane bound glycoprotein. Cancer Res 53:3658-3661
64. Ladona MG, Gonzalez ML, Rane A, Peter RM, de la Torre R (2000) Cocaine metabolism in human fetal and adult liver microsomes is related to cytochrome P450 3A expression. Life Sci 68:431-443
65. Larkin A, O'Driscol L, Kennedy S, Purcell R et al (2004) Investigation of MRP-1 protein and MDR-1 P-glycoprotein expression in invasive breast cancer: a prognostic study. Int J Cancer 112:286-294
66. LeDuc BW, Sinclair PR, Shuster L, Sinclair JF, Evans JE, Greenblatt DJ (1993) Norcocaine and N-hydroxynorcocaine formation in human liver microsomes: role of cytochrome P-450 3A4. Pharmacology 46:294-300
67. Letourneau IJ, Bowers RJ, Deeley RG, Cole SP (2005) Limited modulation of the transport activity of the human multidrug resistance proteins MRP1, MRP2 and MRP3 by nicotine glucuronide metabolites. Toxicol Lett 157:9-19
68. Leslie EM, Deeley RG, Cole SP (2001) Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters. Toxicology 167:3-23
69. Lexiva [package insert] (2005) Research Triangle Park, NC: Glaxo Wellcome Inc.; Nov
70. Li X, Chan WK (1999) Transport, metabolism and elimination mechanisms of anti-HIV agents. Adv Drug Deliv Rev 39:81-103
71. Lin LY, Di Stefano EW, Schmitz DA, Hsu L et al (1997) Oxidation of methamphetamine and methylenedioxymethamphetamine by CYP2D6. Drug Metab Dispos 25:1059-1064
72. Litman T, Brangi M, Hudson E et al (2000) Multidrug-resistant phenotype associated with over expression of the new ABC half transporter, MXR (ABCG2). J Cell Sci 113:2011-2021
73. Litman T, Druley TE, Stein WD, Bates SE (2001) From MDR to MXR: new understanding of multidrug resistance systems, their properties and clinical significance. Cell Mol Life Sci 58:931-959
74. Lown KS, Kolars JC, Thummel KE et al (1994) Inter-patient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab Dispos 22:947-955
75. Malaty LI, Kuper JJ (1999) Drug interactions of HIV protease inhibitors. Drug Saf 20:147-169
76. 8- tetrahydrocannabinol in human liver microsomes. Drug Metab Dispos 28:1291-1296
77. Maurer HH, Bickeboeller-Friedrich J, Kraemer T, Peters FT (2000) Toxicokinetics and analytical toxicology of amphetamine-derived designer drugs ("Ecstasy"). Toxicol Lett 112/113:133-142
78. McCance-Katz EF, Farber S, Selwyn PA, O'Connor A (2000) Decrease in methadone levels with nelfinavir mesylate (letter). Am J Psychiatry 157:481
79. Mummaneni V, Randall D, Chabuel D et al (2002) Steady state pharmacokinetic (PK) interaction study of atazanavir (ATV) with clarithromycin (CLR) in healthy subjects [abs. #H-1717]. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy; September 27-30; San Diego, California
80. Naruhashi K, Tamai I, Inoue N et al (2002) Involvement of multidrug resistance associated protein 2 in intestinal secretion of grepafloxacin in rats. Antimicrob Agents Chemother. 46:344-349
81. Norvir [package insert] (2005) Abbott Laboratories, North Chicago, IL
82. Ouellet D, Hsu A, Granneman GR et al (1998) Pharmacokinetic interaction between ritonavir and clarithromycin. Clin Pharmacol Ther 64:355-362
83. Pal D, Mitra AK (2006) MDR- and CYP3A4-mediated drug-herbal interactions. Life Sci 78:2131-2145
84. Parkinson A (1996) An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol 24:48-57
85. Patel J, Mitra AK (2001) Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs. Pharmacogenomics 2:401-415
86. Patel J, Buddha B, Dey S, Pal D, Mitra AK (2004) In vitro interaction of the HIV protease inhibitor ritonavir with herbal constituents: changes in P-gp and CYP3A4 activity. Am J Ther 11:262-277
87. Pau AK (2002) Polypharmacy problems: Drug interactions in multidrug therapy of HIV infection. www.hiv-druginteractions.org
88. Pellinen P, Honkakoski P, Stenbeck F et al (1994) Cocaine N-demethylation and the metabolism-related hepatotoxicity can be prevented by cytochrome P450 3A inhibitors. Eur J Pharmacol 270:35-43
89. Penzak S, Shen J, Alfar R, Remaley A, Falloon J (2003) Influence of low-dose ritonavir on the pharmacokinetics of the P-glycoprotein (P-gp) substrate digoxin. Program and abstracts of the 4th International Workshop on Clinical Pharmacology of HIV Therapy; March 27-29, Cannes, France. Abstract 2.6
90. Pinzani V, Faucherre V, Peyreire H, Blayac JP (2000) Methadone withdrawal symptoms with nevirapine and efavirenz (letter). Ann Pharmacother 2000 34:405-407
91. Piscitelli SC, Kress DR, Bertz RJ, Pau A, Davey R (2000) The effect of ritonavir on the pharmacokinetics of meperidine and normeperidine. Pharmacotherapy 20:549-553
92. Polk RE, Crouch MA, Israel DS et al (1999) Pharmacokinetic interaction between ketoconazole and amprenavir after single doses in healthy men. Pharmacotherapy 19:1378-1384
93. Reyataz [package insert] (2006) Princeton, NJ: Bristol-Myers Squibb Company; Jan
94. Schuetz EG, Schinkel AH, Relling MV, Schuetz JD (1996) P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P450 3A4 in mice and humans. Proc Natl Acad Sci 93:4001-4005
95. Sharom FJ (1997) P-glycoprotein efflux pump: how does it transport? J Membr Biol 160:161-175
96. Shen DD, Kunze KL, Thummel KE (1997) Enzyme-catalyzed process of first-pass hepatic and intestinal drug extraction. Adv Drug Delivery Rev 27:99-127
97. Sikri V, Pal D, Jain R, Kalyani D, Mitra AK (2004) Cotransport of macrolide and fluoroquinolones, a beneficial interaction reversing P-glycoprotein efflux. Am J Ther 11:433-442
98. Smith KM, Larive LL, Romanelli F (2002) Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. Am J Health Syst Pharm 59:1067-1076
99. Sporanox [package insert] (2000) Titusville, NJ: Janssen Pharmaceutica
100. Synold TW, Dussault I, Forman BM (2001) The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat Med 7:584-590
101. Ueda K, Cardarelli C, Gottesman MM, Pastan I (1987) Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 84:3004-3008
102. Ueda K, Okamura M, Hirai M, Tanigawara T et al (1992) Human P-glycoprotein transports cortisol, aldosterone, and dexamethasone, but not progesterone. J Biol Chem 267:24248-24252
103. Vella S, Floridia M (1998) Saquinavir: clinical pharmacology and efficacy. Clin Pharmacokinet 34:189-201
104. Venkatakrishnan K, Greenblatt DJ, von Molkte LL et al (1998) Alprazolam is another substrate for human cytochrome P450-3A isoforms. J Clin Psychopharmacol 18:256
105. Viracept [package insert] (2004) La Jolla, CA: Agouron Pharmaceuticals, Inc.; Sept
106. Wacher VJ, Wu CY, Benet LZ (1995) Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog 13:129-134
107. Wacher VJ, Silverman JA, Zhang Y, Benet LZ (1998) Role of P-glycoprotein and cytochrome P450 3A4 in limiting oral absorption of peptides and peptidomimectics. J Pharm Sci 87:1322-1330
108. Wacher VJ, Salphati L, Benet LZ (2001) Active secretion and enterocytic drug metabolism barriers to drug absorption. Adv Drug Deliv Rev 46:89-102
109. Watkins PB (1997) The barrier functions of CYP3A4 and P-glycoprotein in the small bowel. Adv Drug Deliv Rev 27:161-170
110. Watkins PB, Wrighton SA, Schuetz EG, Molowa DT, Guzelian PS (1987) Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man. J Clin Invest 80:1029-1036
111. Williams GC, Sinco PJ (1999) Oral absorption of the HIV protease inhibitors: a current update. Adv Drug Deliv Rev 39:211-238
112. Wynn GH, Cozza KL, Zapor MJ, Wortmann GW, Armstrong SC (2005) Antiretrovirals: Part III. Antiretrovirals and drugs of abuse. Psychomatics 46:79-87
113. Xiao JJ, Foraker AB, Swaan PW, Liu S et al (2005) Efflux of Depsipeptide FK228 (FR091228, NSC-630176) is mediated by both P-glycoprotein and MRP1. J Pharmacol EXP Ther 268-276
114. Zaman Gj, Flens MJ, Van Leusden MR et al (1994) Human drug resistance associated protein MRP is a plasma membrane drug-efflux pump. Prod Natl Acad Sci USA 91:8822-8826